RCUS
Arcus Biosciences, Inc.
$25.36
+2.34%
2026-05-08
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Key Fundamentals
Forward P/E
-7.17
EPS (TTM)
$-3.17
ROE
-70.0%
Revenue Growth (YoY)
-39.3%
Profit Margin
-156.4%
Debt/Equity
21.57
Price/Book
4.89
Beta
0.87
Market Cap
$3.10B
Avg Volume (10D)
1.2M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$28.72
60D Low
$18.51
Avg Volume
1.1M
Latest Close
$25.36
Get breakout alerts for RCUS
Sign up for Breakout Scanner to receive daily notifications when RCUS triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Arcus Biosciences, Inc. (RCUS) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors RCUS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. RCUS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.